National shortages are no longer one blanket crisis. In early 2026, the sharper risk is a smaller group of structurally constrained products, especially TICE BCG, plus manufacturer-specific gaps in sterile injectables that can still disrupt care planning and procurement workflows. ASHP shortage statistics show improvement versus 2024 peaks, but not a full normalization.
The overall shortage count has moved down from prior highs, yet high-impact categories remain operationally sensitive. This aligns with Government Accountability Office analysis that shortages have become more durable and continue to disproportionately affect sterile injectables used in hospital and oncology settings. GAO report.
BCG remains allocation-managed through late 2026 planning windows
The clearest structural constraint remains TICE BCG in bladder cancer care. FDA's current biologics shortage page continues to list TICE BCG as available but subject to allocation when demand exceeds planned production and inventory. FDA biologics shortage page. Merck has indicated that demand has exceeded maximum manufacturing capacity, and that capacity expansion is expected to improve supply gradually after late-2026 readiness milestones.
For providers and procurement teams, the practical takeaway is to treat BCG as an allocation-governed therapy rather than a freely available product. AUA guidance continues to prioritize induction for BCG-naive high-risk patients when supply is constrained. AUA BCG shortage guidance.
Injectable disruptions remain uneven by manufacturer and presentation
Injectable steroids remain a pressure point. ASHP's January 2026 triamcinolone acetonide injectable suspension bulletin reflects a mixed pattern of allocation and back order by supplier and presentation. Triamcinolone shortage detail. This is not always an all-or-nothing shortage dynamic, but it can still drive substitution pressure, coverage gaps, and price volatility at facility level.
Metoprolol injection illustrates the same point. Some manufacturer presentations remain constrained while others are available, so procurement decisions should be anchored at manufacturer and NDC granularity, not just molecule name. Metoprolol shortage detail.
IV saline resolved at national level, but local channel variability still matters
FDA announced in August 2025 that the nationwide shortage of sodium chloride 0.9% injection products was resolved, while noting continued monitoring for other IV fluid categories. FDA announcement. Operationally, that means localized back-order and channel disruption can still occur even when a product is no longer classified as a national shortage.
Operational implications for healthcare procurement teams
Early-2026 planning should remain focused on high-impact product groups, disciplined validation of shortage status at NDC/manufacturer level, and maintained substitution pathways for constrained injectables. The current market pattern is less about broad-based universal shortages and more about selective products with outsized clinical and operational impact.